Last reviewed · How we verify
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Sodium Oligomannate Capsules | Sodium Oligomannate Capsules | marketed | Prebiotic oligosaccharide | Gut microbiota (indirect); short-chain fatty acid signaling | Neurology |
Therapeutic area mix
- Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Green Valley (Shanghai) Pharmaceuticals Co., Ltd.:
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd. pipeline updates — RSS
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd. pipeline updates — Atom
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Green Valley (Shanghai) Pharmaceuticals Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/green-valley-shanghai-pharmaceuticals-co-ltd. Accessed 2026-05-17.